Vedolizumab
…m diagnosis. 21/23 (91%) received antiTNF prior to switching to Vedolizumab. 2/23(8.7%) had received Ustekinumab. 19/23 (82.6%) were on Aza…
41articles mentioning drugs
114drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: Vedolizumab ×
Vedolizumab
This drug is selected. Its supporting articles are shown below.
Articles mentioning Vedolizumab
41 articles · page 1 of 4UstekinumabVedolizumab
…Vedolizumab and Ustekinumab were first approved by our trust for treatment of patients with…
vedolizumabCrohn’s diseasemaintenance therapyCD
…ify factors associated with vedolizumab exposure.Results Median vedolizumab trough concentrations were higher in patients achieving clinica…
vedolizumabustekinumabinfliximabVirgen Macarena University HospitalCrohn’s diseaseIBDinflammatory bowel disease
…4 were 51.5% and 45.8% for ustekinumab, and 58.7% and 55.4% for vedolizumab, respectively. In Crohn’s disease, prior infliximab use, male s…
ustekinumabvedolizumab
…ad documented clinical response or remission after switching to ustekinumab. 2 patients not responding subsequently switched from ustekinum…
Vedolizumabruxolitinibacute myeloid leukaemiaacute lymphoblastic leukaemiamyelodysplastic syndromeulcerative colitisgastrointestinal graft-versus-host disease (GI-GVHD)GI-GVHDMHNmalignant haematological neoplasms (MHN)
…kaemia (n=2), myelodysplastic syndrome (n=2), and others (n=4). Vedolizumab was used as third-line therapy in seven patients, fourth-line i…
UstekinumabVedolizumabRisankizumabTNFiinfliximabinflammatory bowel diseaseIBDileocolonic disease
…ent followed by another anti-TNFa treatment or Vedolizumab then Ustekinumab. Median age at diagnosis was 8 years. We found that (40%) switc…
infliximabadalimumabVedolizumabazathioprineQuantiFERONlevofloxacinrifampicinpyridoxine
…iagnosed with Crohn’s disease at age 10. Initially treated with infliximab, he was switched to adalimumab due to allergic reaction. He did…
ustekinumabvedolizumabUzpruvoWezenlaPyzchivaSimple Clinical Colitis Activity Indexulcerative colitisCrohn’s diseaseCDinflammatory bowel disease
… rates and stable clinical disease activity and biomarkers with ustekinumab biosimilars. Biosimilar ustekinumab was well tolerated and appe…
vedolizumabVedolizumab64ustekinumabAzathioprineP19 inhibitorsP19 inhibitors51JAK inhibitors52ulcerative colitisCrohn’s diseaseInflammatory Bowel Disease+3 more
… restricted with only 50.7% of services reporting access.In CD, vedolizumab was accessible in 64/71 services (90.1%), including 31 (43.7%) …
adalimumabrisankizumabvedolizumabustekinumabinfliximabJAK-inhibitorsorofacial granulomatosisOrofacial granulomatosis (OFG)
…l surgery.Advanced therapies used for treatment of OFG included adalimumab (n=56), infliximab (n=52), ustekinumab (n=23), risankizumab (n=…
96.3%
VedolizumabVDZCrohn’s diseaseCDCDST
…Introduction The Vedolizumab Clinical Decision Support Tool (VDZ-CDST) is a validated tool t…